The most commonly reported side effects of lerodalcibep include cerebrovascular accident, alanine aminotransferase increased, and adverse event, based on 2 FDA adverse event reports from 2021 to 2025.
Percentages show how often each reaction appears relative to total reports for lerodalcibep.
These are voluntary reports and do not establish that lerodalcibep caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside lerodalcibep. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Also suspected
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
Conditions and purposes for which patients were taking lerodalcibep when the adverse event was reported.
Lerodalcibep is sold under the brand name Lerochol.
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.